newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

  • Immunovant reports all IMVT-1402 clinical development timelines remain on track across six indications: Graves' disease, myasthenia gravis, CIDP, D2T RA, Sjögren's disease, & cutaneous lupus erythematosus.
  • The company expects to report D2T RA program updates & CLE proof-of-concept data in H2 2026, GD & MG data in 2027, & CIDP & SjD data in 2028.
  • Cash & cash equivalents totaled $797.8 million as of June 30, 2026, providing runway to a potential GD launch.
  • R&D expenses were $142.6 million for Q1 2026, rising from $101.2 million in 2025 due to IMVT-1402 trial activities & manufacturing costs while winding down batoclimab trials.
  • G&A expenses decreased to $17.7 million in Q1 2026 from $26.0 million in 2025, driven by lower personnel, professional, & IT costs.
  • Net loss for the quarter ended June 30, 2026, was $153.2 million ($0.75 per share), compared to $120.6 million ($0.71 per share) in the prior year period.
  • There were 206,264,878 shares of common stock issued & outstanding as of June 30, 2026.
  • Roivant will host a live conference call & webcast at 8:00 a.m. ET on August 6, 2026, to discuss these results.